Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Jishu Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0529-272X; OpenAlex author ID A5052717586. Sources: OpenAlex.

Their work

Papers
38 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
82
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: 5 papers · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 7 papers · 2026: 2 papers

Papers 38

  1. Post-surgery weight changes in pancreatic cancer: a prospective study on factors and survival impact. Co-author DOI 10.1186/s12957-026-04202-z↗
  2. Co-evolution of Oncogenic KRAS Signaling and LILRB high Macrophages Drives Pancreatic Cancer Recurrence Co-author DOI 10.64898/2026.03.05.709991↗
  3. Comparison of Radical Antegrade Modular Pancreatosplenectomy Versus Standard Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Mat… Co-author DOI 10.1002/wjs.12630↗
  4. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-024-01358-7↗
  5. The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal … Co-author DOI 10.1186/s12885-025-14262-1↗
  6. Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. Co-author DOI 10.1186/s12885-025-14601-2↗
  7. Correction: A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Co-author DOI 10.1186/s12967-025-06581-5↗
  8. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  9. [Retracted] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Last author DOI 10.3892/mmr.2025.13475↗
  10. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20230615-000234↗
  11. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. First author DOI 10.1001/jamanetworkopen.2021.48721↗
  12. The distinct genetic features of pancreatic cancer in Chinese population. First author DOI 10.1016/j.ebiom.2022.103960↗
  13. [Corrigendum] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Last author DOI 10.3892/mmr.2022.12738↗
  14. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  15. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  16. Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis. Co-author DOI 10.3390/cancers14010057↗
  17. [Comparison of radical antegrade modular pancreatosplenectomy with conventional distal pancreatectomy for pancreatic adenocarcinoma of the body and tail]. Co-author DOI 10.3760/cma.j.cn112139-20200413-00301↗
  18. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. First author DOI 10.1002/cam4.2145↗
  19. Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study. Co-author DOI 10.1007/s00423-019-01766-1↗
  20. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Co-author DOI 10.1016/j.canlet.2018.11.007↗
  21. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2017.12.021↗
  22. PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition. Co-author DOI 10.1159/000489382↗
  23. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. Last author DOI 10.1186/s12876-018-0891-y↗
  24. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. Last author DOI 10.1186/s13046-018-0807-2↗
  25. miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Last author DOI 10.3892/mmr.2018.8941↗
  26. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase reg… Co-author DOI 10.1186/s12943-017-0619-6↗
  27. A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Co-author DOI 10.1186/s12967-017-1308-3↗
  28. PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0500-x↗
  29. MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Co-author DOI 10.3892/or.2017.6036↗
  30. The Expression and Prognostic Roles of MCMs in Pancreatic Cancer. Last author DOI 10.1371/journal.pone.0164150↗
  31. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.11953↗
  32. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. Co-author DOI 10.1186/1471-2407-14-738↗
  33. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.27715↗
  34. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Co-author DOI 10.1016/j.canlet.2012.11.005↗
  35. CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Co-author DOI 10.3892/ijo.2013.2015↗
  36. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Co-author DOI 10.3892/or.2013.2297↗
  37. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreat… Co-author DOI 10.1002/ijc.26290↗
  38. Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an i… Co-author DOI 10.1097/mpa.0b013e318217945e↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 24 shared papers, 2011–2026 · strength 2.87
  2. Yi Miao · 27 shared papers, 2011–2025 · strength 2.68
  3. Min Tu · 15 shared papers, 2013–2026 · strength 1.89
  4. Lingdi Yin · 13 shared papers, 2016–2026 · strength 1.75
  5. Yunpeng Peng · 14 shared papers, 2014–2025 · strength 1.73
  6. Wentao Gao · 17 shared papers, 2011–2025 · strength 1.66
  7. Junli Wu · 15 shared papers, 2011–2025 · strength 1.64
  8. Zipeng Lu · 13 shared papers, 2011–2025 · strength 1.43
  9. Xinchun Liu · 10 shared papers, 2016–2025 · strength 1.08
  10. Yi Miao · 7 shared papers, 2013–2025 · strength 1.02
  11. Chunhua Xi · 7 shared papers, 2016–2024 · strength 0.72
  12. Yang Feng Wu · 3 shared papers, 2024–2025 · strength 0.68
  13. Qianqian Wang · 2 shared papers, 2025 · strength 0.50
  14. Dong Xu · 2 shared papers, 2025 · strength 0.50
  15. Kuirong Jiang · 3 shared papers, 2013–2025 · strength 0.50
  16. Kai Zhang · 4 shared papers, 2019–2024 · strength 0.50
  17. Ying Xin · 3 shared papers, 2018–2025 · strength 0.49
  18. Jingjing Zhang · 5 shared papers, 2014–2025 · strength 0.49
  19. Qiuyang Chen · 4 shared papers, 2017–2025 · strength 0.45
  20. Bin Chen · 2 shared papers, 2022–2025 · strength 0.41
  21. Baobao Cai · 4 shared papers, 2013–2025 · strength 0.39
  22. Jian‐Min Chen · 4 shared papers, 2013–2025 · strength 0.36
  23. Yue Fu · 5 shared papers, 2016–2018 · strength 0.36
  24. Qingmei Sun · 1 shared paper, 2026 · strength 0.33
  25. Lei Cui · 1 shared paper, 2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.